Loading...
Searching Database & Compiling the results...
This process involves analyzing complex genetic data and may take a moment.
PDX model details
| PDX ID | 201.1A Cx |
|---|---|
| Host Strain(and Source) | NSG Source: Monash University |
| Host Strain Immune system Humanized | NO |
| Host Type | Castrate |
| Graft Site | Subcutaneous |
| Current Generation (* indicates number of generations grown in Castrate host) |
61 (30*) |
| Average PDX Generation Time (days +/- SEM) | 39 ± 2 |
| Tumour preparation | Tumor solid |
| Tumour Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed | Routine QA every 2-3 passages |
| Associated meta data | |
| PDX model availability | Yes (fixed, frozen or cryopreserved tissue) |
| Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID | 34413304; 30049486 |
| Markers | 201.1A Cx |
|---|---|
| AR | Y |
| PSA | Y |
| PSMA | Y |
| NE | N |
| ERG | Y |
This table displays curated CNVs
| PDX ID | Gene Symbol | CNV Log2 | CNV Copy | CNV Call | Experiments name | Platform | Reference genome |
|---|---|---|---|---|---|---|---|
| 201.1A Cx | CUL3 | -1.025 | 0.983 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 201.1A Cx | USP28 | -0.901 | 1.071 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 201.1A Cx | CDKN1B | -1.069 | 0.953 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 201.1A Cx | TP53 | -0.937 | 1.044 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 201.1A Cx | ERF | -0.908 | 1.066 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 201.1A Cx | CDKN2A | -0.997 | 1.002 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 201.1A Cx | RB1 | -28.028 | 7.310e-09 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 201.1A Cx | PTEN | -16.819 | 1.730e-05 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
Clinical Information
| Sample Number | 201.1A |
|---|---|
| Sample Site | Dura |
| Sample source | Autopsy |
| Pathology Tumour Diagnosis | Adenocarcinoma |
| Gleason Score | None |
| Primary Gleason Score | None |
| Secondary Gleason Score | None |
| Tertiary Gleason Score | None |
| ISUP Grade Group | |
| Tumour Grade | |
| D'Amico Risk Classification | |
| Tumour Volume (in cc) | 0.0 |
| Treatment Prior to Specimen Collection | ADT, docetaxel, cabazitaxel, abiraterone, enzalutamide |
Patient Information
| Patient Number | 201 |
|---|---|
| Sex | Male |
| Diagnosis | Prostate Cancer |
| PSA at diagnosis (ng/mL) | NA |
| Consent to share data | Yes, subject to ethical review |
| Patient Tumour Collection (Current Model) | |
|---|---|
| Tumour sample ID | 201.1A |
| Patient Age (binned in 5 year age groups) | 70-74 |
This table displays curated sequence variants
| PDX ID | Gene Symbol | Total Read Depth | Alternate Frequency | Consequence | Exon | GnomAD AF | CADD PHRED score | ClinVar significance | Platform | Experiments Name | Reference | Library Type | Instrument Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 201.1A Cx | ZMYM3 | 198 | 1.0 | Stop gained | '2/25 | . | 35 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | AR | 280 | 1.0 | Missense variant | '4/8 | . | 23.2 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | AR | 236 | 0.99 | Missense variant | '8/8 | . | 25.3 | Pathogenic | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | MLH1 | 70 | 0.93 | Inframe insertion,splice region variant | '10/19 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | MLH1 | 84 | 0.79 | Splice acceptor variant | . | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | STAT4 | 249 | 0.55 | Splice acceptor variant | . | . | 28.5 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | TGFBR2 | 162 | 0.54 | Frameshift variant | '4/8 | 0.0003621 | 35 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | ERBB4 | 228 | 0.54 | Splice donor variant | . | . | 34 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | MUTYH | 499 | 0.54 | Missense variant | '13/16 | 0.0007924 | 20.7 | Conflicting interpretations of pathogenicity | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | ARFRP1 | 348 | 0.53 | Missense variant | '7/7 | . | 29.3 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | LRP2 | 584 | 0.53 | Missense variant | '25/79 | . | 25.2 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | MYH14 | 395 | 0.51 | Frameshift variant | '25/43 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | AXIN2 | 273 | 0.51 | Frameshift variant | '7/11 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | CACNA1H | 438 | 0.5 | Missense variant | '9/35 | 8.90E-05 | 5.716 | Uncertain significance | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | SPTA1 | 321 | 0.5 | Missense variant,splice region variant | '4/52 | . | 33 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | TCERG1 | 330 | 0.49 | Frameshift variant | '20/22 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | MYH14 | 425 | 0.49 | Splice acceptor variant | . | . | 26.7 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | GSK3B | 287 | 0.49 | Missense variant | '6/12 | . | 27.4 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | GLI2 | 387 | 0.49 | Missense variant | '14/14 | . | 24.3 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | GLI2 | 343 | 0.48 | Missense variant | '4/14 | 4.06E-06 | 29.6 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | MSH2 | 304 | 0.48 | Missense variant | '16/16 | 6.12E-05 | 27.7 | Uncertain significance | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | KMT2D | 457 | 0.47 | Missense variant | '48/54 | . | 33 | Conflicting interpretations of pathogenicity | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | OGDH | 563 | 0.47 | Frameshift variant | '22/23 | . | 35 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | KMT2C | 398 | 0.47 | Stop gained | '36/59 | 0 | 40 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | SIX3 | 289 | 0.47 | Frameshift variant | '1/2 | 0 | 28.8 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | ARID4A | 314 | 0.47 | Frameshift variant | '16/24 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | BBC3 | 534 | 0.47 | Frameshift variant | '4/4 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | MYH14 | 443 | 0.46 | Missense variant | '30/43 | . | 28 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | XIRP2 | 338 | 0.46 | Frameshift variant | '9/11 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | ZFHX3 | 496 | 0.46 | Frameshift variant | '2/10 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | TOP2A | 415 | 0.46 | Frameshift variant | '34/35 | 3.31E-05 | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | ATR | 218 | 0.46 | Frameshift variant | '20/47 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | PPP2R1A | 507 | 0.46 | Missense variant | '4/15 | . | 27.8 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | SIRT1 | 209 | 0.45 | Frameshift variant | '1/9 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | NCAM1 | 239 | 0.45 | Frameshift variant | '1/19 | . | 24.1 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | NCOR2 | 583 | 0.45 | Frameshift variant | '29/47 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | AIP | 467 | 0.45 | Missense variant | '6/6 | . | 29.7 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | MGA | 339 | 0.44 | Splice donor variant | . | . | 25.6 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | AXIN2 | 481 | 0.44 | Frameshift variant | '8/11 | 0 | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | BLM | 281 | 0.43 | Frameshift variant | '7/22 | 2.95E-05 | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | CTNNB1 | 448 | 0.43 | Missense variant | '3/15 | . | 29.9 | Pathogenic/likely pathogenic, other | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | TERT | 479 | 0.42 | Missense variant | '2/16 | . | 5.144 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | BRCA2 | 286 | 0.42 | Frameshift variant | '11/28 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | CHEK2 | 367 | 0.42 | Splice donor variant | . | . | 33 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | FANCE | 474 | 0.41 | Frameshift variant | '4/10 | 8.53E-05 | 22.8 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | MSH6 | 374 | 0.41 | Frameshift variant | '4/10 | . | 24.1 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | PARP10 | 398 | 0.39 | Missense variant,splice region variant | '10/11 | . | 24.3 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | NFE2L1 | 329 | 0.39 | Frameshift variant | '2/6 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | KMT2C | 322 | 0.34 | Frameshift variant | '38/59 | 4.07E-05 | 24 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | ASXL1 | 559 | 0.33 | Frameshift variant | '13/13 | 0.0004861 | 34 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.1A Cx | GRM7 | 456 | 0.27 | Frameshift variant | '3/10 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
This table displays drug response data
qd->once daily; qwk->once weekly Click any column header to sort.
qd->once daily; qwk->once weekly Click any column header to sort.
| PDX ID | Treatment1 | Dose (mg/kg) | Frequency | Treatment2 | Dose (mg/kg) | Frequency | Response |
|---|---|---|---|---|---|---|---|
| 201.1A Cx | Carboplatin | 50 | qwk | NA | NA | NA | No response |
| 201.1A Cx | Talazoparib | 0.33 | qd | Carboplatin | 50 | qwk | No response |
| 201.1A Cx | Talazoparib | 0.33 | qd | NA | NA | NA | No response |